Founded in 2022, Chengdu Chimera Biologics Co., Ltd. operates at the cutting-edge intersection of protein engineering and synthetic biology, with a specialized focus on the development of long-acting peptides and conjugate drugs. The company recently announced the successful completion of a Pre-A round financing, raising tens of millions of yuan. This round was led by Forward Capital, with Chengdu Science and Technology Innovation Investment Group joining as a follow-on investor, and Danstone Capital acting as the exclusive financial advisor. The proceeds from this financing will be predominantly allocated to bolstering the company's proprietary chimeric translation system technology platform and accelerating preclinical research on its existing candidate molecules.

Leveraging the world's pioneering chimeric translation system technology, Chengdu Chimera Biologics is capable of efficiently incorporating over a hundred types of unnatural amino acids at specific sites within both prokaryotic and eukaryotic cells. This capability endows proteins with novel structural and functional attributes. This innovative technology effectively overcomes the challenges associated with synthesizing long-chain peptide drugs containing unnatural amino acids and offers the potential for large-scale engineering amplification of the underlying platform.

The company's R&D pipeline encompasses multi-target peptide drugs designed for the treatment of metabolic chronic diseases, as well as groundbreaking drugs targeting nonsense mutation genetic disorders. Its core scientific endeavors are closely aligned with fundamental research conducted at Zhejiang University. Founder Dr. Lin Shixian brings a stellar academic pedigree and industrial translation expertise to the table, having assembled a team of professional full-time researchers. At present, relevant drug pipelines have demonstrated clear efficacy and pharmacokinetic results.

The investors and financial advisor involved in this round express confidence in the value of the company's underlying technology platform and the promising development prospects of its drug pipeline.